---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-241397"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2024-10-23T23:59:59+00:00"
generated_at: "2026-05-30T11:06:16.891995+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# RMC-6236 shows 8.5-month median PFS in 2L metastatic PDAC

## Summary
- Median PFS of 8.5 months (95% CI: 5.3-11.7) in 2L PDAC with KRAS G12X; 4.4 months in 3L+.
- Median OS of 14.5 months in 2L PDAC; 6-month OS rate 89% (KRAS G12X) and 91% (broader RAS mutant).
- ORR 29% (2L) and 22% (3L+); disease control rate 91% (2L) and 89% (3L+).
- Safety: 98% any grade TRAEs, 29% Grade≥3; no discontinuations; mean dose intensity 92%.
- Data cutoff July 23, 2024; 127 PDAC patients across 160-300 mg daily doses.

## SEC filing metadata
- accession: 0001193125-24-241397
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2024-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312524241397/0001193125-24-241397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312524241397/d750511d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-241397
- JSON: https://secwatch.observer/filing/0001193125-24-241397.json
- Plain text: https://secwatch.observer/filing/0001193125-24-241397.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.